Literature DB >> 11395314

Synthesis and evaluation of a macrocyclic bifunctional chelating agent for use with bismuth radionuclides.

K Garmestani1, Z Yao, M Zhang, K Wong, C W Park, I Pastan, J A Carrasquillo, M W Brechbiel.   

Abstract

The detailed synthesis of the bifunctional chelating agent 2-(p-isothiocyanatobenzyl)-1,4,7,10,13-pentaazacyclopentadecane-N,N',N",N"',N""-pentaacetic acid (BF_PEPA) is reported. This ligand was conjugated to monoclonal antibody B3 and the resultant immunoconjugate radiolabeled with (205,206)Bi. The in vivo stability of the radiolabeled immunoconjugate, and targeting characteristics were determined by biodistribution studies in A431 xenograft tumor-bearing mice sacrificed at 0.5, 1, 2, 4, and 24 hr. Results indicate that BF_PEPA appears to not be a suitable bifunctional chelating agent for sequestering isotopes of Bi(III) for radioimmunotherapy applications.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11395314     DOI: 10.1016/s0969-8051(00)00203-1

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  8 in total

1.  Targeting HER2: a report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials.

Authors:  Diane E Milenic; Karen J Wong; Kwamena E Baidoo; Tapan K Nayak; Celeste A S Regino; Kayhan Garmestani; Martin W Brechbiel
Journal:  MAbs       Date:  2010-09-01       Impact factor: 5.857

Review 2.  Bifunctional chelates for metal nuclides.

Authors:  M W Brechbiel
Journal:  Q J Nucl Med Mol Imaging       Date:  2007-11-28       Impact factor: 2.346

3.  Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications.

Authors:  Diane E Milenic; Karen J Wong; Kwamena E Baidoo; Geoffrey L Ray; Kayhan Garmestani; Mark Williams; Martin W Brechbiel
Journal:  Cancer Biother Radiopharm       Date:  2008-10       Impact factor: 3.099

4.  Evaluation of cetuximab as a candidate for targeted α-particle radiation therapy of HER1-positive disseminated intraperitoneal disease.

Authors:  Diane E Milenic; Kwamena E Baidoo; Young-Seung Kim; Martin W Brechbiel
Journal:  MAbs       Date:  2015       Impact factor: 5.857

5.  Rational design and generation of a bimodal bifunctional ligand for antibody-targeted radiation cancer therapy.

Authors:  Hyun-Soon Chong; Xiang Ma; Thien Le; Baidoo Kwamena; Diane E Milenic; Erik D Brady; Hyun A Song; Martin W Brechbiel
Journal:  J Med Chem       Date:  2007-12-07       Impact factor: 7.446

6.  Synthesis and biological evaluation of a novel decadentate ligand DEPA.

Authors:  Hyun-Soon Chong; Sooyoun Lim; Kwamena E Baidoo; Diane E Milenic; Xiang Ma; Fang Jia; Hyun A Song; Martin W Brechbiel; Michael R Lewis
Journal:  Bioorg Med Chem Lett       Date:  2008-09-19       Impact factor: 2.823

Review 7.  Bismuth-213 for Targeted Radionuclide Therapy: From Atom to Bedside.

Authors:  Stephen Ahenkorah; Irwin Cassells; Christophe M Deroose; Thomas Cardinaels; Andrew R Burgoyne; Guy Bormans; Maarten Ooms; Frederik Cleeren
Journal:  Pharmaceutics       Date:  2021-04-21       Impact factor: 6.321

8.  3p-C-NETA: A versatile and effective chelator for development of Al18F-labeled and therapeutic radiopharmaceuticals.

Authors:  Stephen Ahenkorah; Erika Murce; Christopher Cawthorne; Jessica Pougoue Ketchemen; Christophe M Deroose; Thomas Cardinaels; Yann Seimbille; Humphrey Fonge; Willy Gsell; Guy Bormans; Maarten Ooms; Frederik Cleeren
Journal:  Theranostics       Date:  2022-08-08       Impact factor: 11.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.